Instil Bio shares rise on immunotherapy trial updates

Stock Information for Instil Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Instil Bio Inc.

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.